摘要
目的 探析培美曲塞二钠联合卡铂治疗晚期肺腺癌的临床效果。方法 选取本院2011年3月至2014年2月首次确诊并初次收治的204例晚期肺腺癌患者为研究对象,按照随机数表法将其分为研究组和对照组,每组各102例。对照组患者采用吉西他滨联合卡铂化疗,研究组患者采用培美曲塞二钠联合卡铂化疗。比较两组患者近期疗效、不良反应发生情况、无进展生存期及1年生存率。结果研究组患者治疗有效率及疾病控制率均显著优于对照组（P〈0.05）。研究组患者Ⅰ~Ⅱ度及Ⅲ~Ⅳ度白细胞减少率均显著低于对照组（P〈0.05）,两组患者其他不良反应发生率比较差异均无显著性（P〉0.05）。研究组患者无进展生存期及1年生存率显著高于对照组（P〈0.05）。结论 培美曲塞二钠联合卡铂治疗晚期肺腺癌近期疗效显著,可显著延长患者无进展生存期,提高1年生存率,安全性好。
Objective To investigate the clinical effect ofpemetrexed disodium combined with carboplatin in the treatment of advanced lung adenocarcinoma. Method 204 cases of advanced lung adenocarcinoma patients who were first diagnosed and treated were selected in our hospital from March 2011 to February 2014 as the research objects. According to the random number table method they were divided into study group and control group, 102 cases in each group. Control group patients were treated by gemcitabine combined with carboplatin chemotherapy, study group patients were treated by pemetrexed disodium combined with carboplatin chemotherapy. The short term curative effect, adverse reaction, progression free survival and 1 year survival rate of the two groups were compared. Result The effective rate and disease control rate of study group were significantly better than control group （P 〈 0.05）. The rates of leukocyte reduction for Ⅰ - Ⅱ degree and Ⅲ-Ⅳ degree in study group were significantly lower than control group （P 〈 0.05）. There was no significant difference in the incidence of other adverse reactions between the two groups （P 〉 0.05）. The progression-free survival and one year survival rate in study group were significantly higher than control group （P 〈 0.05）. Conclusion The recent curative effect ofpemetrexed disodium combined with carboplatin in the treatment of advanced lung adenocarcinoma is remarkable can significantly prolong patients＇ progression-free surial, improve the 1 year survival rate, the security is good.
出处
《中国医学前沿杂志（电子版）》
2015年第12期50-53,共4页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
肺腺癌
培美曲塞二钠
卡铂
Lung adenocarcinoma
Pemetrexed disodium
Carboplatin
